Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cytek Biosciences ( (CTKB) ) just unveiled an announcement.
On June 18, 2025, Cytek Biosciences held its annual meeting of stockholders, with approximately 81.4% of outstanding shares represented. During the meeting, Richard Chin, MD, and Deborah Neff were elected as Class I directors to serve until 2028. Additionally, the executive compensation for 2024 was approved, and Deloitte & Touche LLP was ratified as the independent registered public accounting firm for 2025.
The most recent analyst rating on (CTKB) stock is a Buy with a $8.25 price target. To see the full list of analyst forecasts on Cytek Biosciences stock, see the CTKB Stock Forecast page.
Spark’s Take on CTKB Stock
According to Spark, TipRanks’ AI Analyst, CTKB is a Neutral.
The stock score reflects the company’s solid financial position but highlights challenges in achieving profitability and stable cash flows. While the earnings call revealed some positive growth in service revenue and APAC markets, the overall revenue decline and bearish technical indicators weigh heavily on the stock’s outlook.
To see Spark’s full report on CTKB stock, click here.
More about Cytek Biosciences
Cytek Biosciences, Inc. operates in the biotechnology industry, focusing on providing advanced cell analysis solutions. The company is known for its innovative products and services that cater to the needs of researchers and clinicians in the life sciences sector.
Average Trading Volume: 1,098,786
Technical Sentiment Signal: Sell
Current Market Cap: $373.6M
See more insights into CTKB stock on TipRanks’ Stock Analysis page.